HomeCompareORXOF vs CL

ORXOF vs CL: Dividend Comparison 2026

ORXOF yields 87.48% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORXOF wins by $2.26M in total portfolio value
10 years
ORXOF
ORXOF
● Live price
87.48%
Share price
$2.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.30M
Annual income
$708,964.09
Full ORXOF calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — ORXOF vs CL

📍 ORXOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORXOFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORXOF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORXOF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOF
Annual income on $10K today (after 15% tax)
$7,435.92/yr
After 10yr DRIP, annual income (after tax)
$602,619.48/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, ORXOF beats the other by $597,985.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOF + CL for your $10,000?

ORXOF: 50%CL: 50%
100% CL50/50100% ORXOF
Portfolio after 10yr
$1.17M
Annual income
$357,207.90/yr
Blended yield
30.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

ORXOF
No analyst data
Altman Z
-0.2
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOF buys
0
CL buys
9
PoliticianChamberTickerTypeAmountDate
John Boozman🏛 Senate$CL▼ Sell$1,001 - $15,0002025-10-09
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-10-07
Rick Larsen🏢 House$CL▼ Sell$1,001 - $15,0002025-10-06
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$CL▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CL▼ Sell$1,001 - $15,0002025-09-11
Tim Moore🏢 House$CL▼ Sell$1,001 - $15,0002025-09-10
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-08-26
Lisa McClain🏢 House$CL▲ Buy$1,001 - $15,0002025-08-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORXOFCL
Forward yield87.48%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$2.30M$41.0K
Annual income after 10y$708,964.09$5,451.69
Total dividends collected$2.02M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ORXOF vs CL ($10,000, DRIP)

YearORXOF PortfolioORXOF Income/yrCL PortfolioCL Income/yrGap
1← crossover$19,448$8,748.14$11,014$313.84+$8.4KORXOF
2$36,710$15,900.47$12,200$415.44+$24.5KORXOF
3$67,330$28,049.97$13,607$553.09+$53.7KORXOF
4$120,123$48,080.71$15,301$741.41+$104.8KORXOF
5$208,701$80,169.36$17,374$1,002.00+$191.3KORXOF
6$353,484$130,173.43$19,958$1,367.44+$333.5KORXOF
7$584,283$206,054.85$23,243$1,887.87+$561.0KORXOF
8$943,494$318,311.52$27,512$2,642.43+$916.0KORXOF
9$1,489,918$480,379.75$33,197$3,759.22+$1.46MORXOF
10$2,303,177$708,964.09$40,973$5,451.69+$2.26MORXOF

ORXOF vs CL: Complete Analysis 2026

ORXOFStock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ORXOF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOF vs SCHDORXOF vs JEPIORXOF vs OORXOF vs KOORXOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.